Preview

Медицинский Совет

Расширенный поиск

Выбор оптимального препарата для лечения рассеянного склероза

https://doi.org/10.21518/2079-701X-2015-5-7-18

Полный текст:

Аннотация

В статье приводится обзор препаратов, применяемых в настоящее время для лечения рассеянного склероза. Рассматриваются две основные тактики назначения ПИТРС (препараты, изменяющие течение рассеянного склероза), факторы, которые необходимо учитывать при выборе терапии, а также вопросы замены препарата при неэффективности или непереносимости ранее назначенной терапии.

Об авторе

А. Н. Бойко
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва
Россия


Список литературы

1. Гусев Е.И., Бойко А.Н. Некоторые клинические и медико-социальные аспекты новых методов патогенетического лечения рассеянного склероза. Ж. неврологии и психиатрии, 2001, 12: 7-12.

2. Бойко А.Н. Патогенетическое лечение рассеянного склероза и других аутоиммунных заболеваний нервной системы. Аутоиммунные заболевания в неврологии. Клиническое руководство под ред. И.А. Завалишина, МА. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина и А.В. Переседовой. М.: РООИ «Здоровье человека», 2014, 1: 285-344.

3. Kita M. FDA-approved preventative therapies for MS: first-Line agents. Neurol Clin., 2011, 29(2): 401-409.

4. Confavreux C, O'Connor P, Comi G et aL. Oral teri-fLunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, doubLe-bLind, pLacebo-controLLed phase 3 triaL. The Lancet Neurology, 2014, 13(3): 247-256.

5. Comi G, Jeffery D, Kappos L et aL. PLacebo-controLLed triaL of oraL Laquinimod for muLtipLe scLerosis. N Engl J Med., 2012, 366(11): 1000-1009.

6. MartineLLi Boneschi F, Rovaris M et aL. Mitoxantrone for muLtipLe scLerosis. Cochrane Database of Systematic Reviews, 2005, Issue 4: CD002127.

7. Oh J, O'Connor PW Safety, toLerabiLity, and efficacy of oraL therapies for reLapsing-remitting muLtipLe scLerosis. CNS Drugs., 2013, 27(8): 591-609.

8. ELovaara I, Kuusisto HW. Intravenous immuno-gLobuLins are a therapeutic option in the treatment of muLtipLe scLerosis reLapse. Clin Neuropharmacol., 2011, 34(2): 84-89.

9. Jacobs LD, Cookfair DL, Rudick RA et aL. The MuLtipLe ScLerosis CoLLaborative Research Group. IntramuscuLar interferon beta-1a for disease progression in reLapsing muLtipLe scLerosis. Ann Neurol, 1996, 39(3): 285-294.

10. PRISMS (Prevention of ReLapses and DisabiLity by Interferon beta-1a SubcutaneousLy in MuLtipLe ScLerosis) Study Group. Randomised doubLe-bLind pLacebo-controLLed study of interferon beta-1a in reLapsing/remitting muLtipLe scLerosis. Lancet, 1998, 352(9139): 1498-1504.

11. Paty DW, Li DK, UBC MS/MRI Study Group and the IFNB MuLtipLe ScLerosis Study Group. Interferon beta-1b is effective in reLapsing-remitting muLtipLe scLerosis: II: MRI anaLysis resuLts of a muLticenter, randomized, doubLe-bLind, pLacebo-controLLed triaL. Neurology. 1993, 43(4): 662-667.

12. Johnson KP, Brooks BR, Cohen JA, et aL, the CopoLymer 1 MuLtipLe ScLerosis Study Group. CopoLymer 1 reduces reLapse rate and improves disabiLity in reLapsing-remitting muLtipLe scLerosis: resuLts of a phase III muLticenter, doubLe-bLind pLacebocontroLLed triaL. Neurology. 1995, 45(7): 1268-1276.

13. Comi G, FiLippi M, WoLinsky JS, European/ Canadian GLatiramer Acetate Study Group. European/Canadian muLticenter, doubLe-bLind, randomized, pLacebo-controLLed study of the effects of gLatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with reLapsing muLtipLe scLerosis. Ann Neurol. 2001, 49(3): 290-297.

14. PoLman CH, O'Connor Pw, Havrdova E, et aL. A randomized, pLacebo-controLLed triaL of nataLi-zumab for reLapsing muLtipLe scLerosis. N Engl J Med. 2006, 354(9): 899-910.

15. MiLLer DH, Soon D, Fernando KT, et aL. MRI outcomes in a pLacebo-controLLed triaL of nataLizum-ab in reLapsing MS. Neurology. 2007, 68(17): 1390-1401.

16. Kappos L, AnteL J, Comi G, et aL. OraL fingoLimod (FTY720) for reLapsing muLtipLe scLerosis. N Engl J Med. 2006, 355(11): 1124-1140.

17. Kappos L, Radue EW, O'Connor P, et aL. A pLacebo-controLLed triaL of oraL fingoLimod in reLapsing muLtipLe scLerosis. N Engl J Med. 2010, 362(5): 387-401.

18. Rommer PS, Stuve O. Management of secondary progressive muLtipLe scLerosis: prophyLactic treatment-past, present, and future aspects. Curr Treat Options Neurol. 2013, 15(3): 241-258.

19. Hartung HP, Gonsette R, Konig N et aL. Mitoxantrone in progressive muLtipLe scLerosis: a pLacebo-controLLed, doubLe-bLind, randomized muLticentre triaL. Lancet 2002, 360: 2018-2025.

20. KLawiter EC, Cross AH, Naismith RT. The present efficacy of muLtipLe scLerosis therapeutics: Is the new 66% just the oLd 33%?_Neurology. 2009, 73(12): 984-990.

21. Poser CM, Paty DW, Scheinberg L, et aL. New diagnostic criteria for muLtipLe scLerosis: guideL-Lines for research protocoLs. Ann Neurol 1983, 13: 227-231.

22. McDonaLd WI, Compston A, Edan G et aL. Recommended diagnostic criteria for muLtipLe scLerosis: guideLines from the InternationaL PaneL on the Diagnosis of MuLtipLe ScLerosis. Ann. Neurol 2001, 50 (1): 121-127.

23. PoLman CH, ReingoLd SC, Edan G et aL. Diagnostic criteria for muLtipLe scLerosis: 2005 revisions to the McDonaLd criteria. Ann. Neurol. 2005, 58: 840-846.

24. PoLman CH, ReingoLd SC, BanweLL B, et aL. Diagnostic criteria for muLtipLe scLerosis: 2010 revisions to the McDonaLd criteria. Ann Neurol. 2011, 69(2): 292-302.

25. Sormani MP, Tintore M, Rovaris M, Rovira A, VidaL X, Bruzzi P, FiLippi M, MontaLban X. WiLL Rogers phenomenon in muLtipLe scLerosis. Ann Neurol. 2008, 64(4): 428-433.

26. Sormani MP.The WiLL Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci. 2009, 287 SuppL 1: S46-49.

27. Schwid SR, Panitch HS. FuLL resuLts of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a muLticenter, randomized, assessor-bLinded comparison of Low-dose weekLy versus high-dose, high-frequency interferon beta-1a for reLapsing muLtipLe scLerosis. Clin Ther. 2007, 29: 2031-2048.

28. Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, CLerico M, Pipieri A, Verdun E, Giordano L, DureLLi L, INCOMIN TriaL Study Group. Every-other-day interferon beta-1b versus once-weekLy interferon beta-1a for muLtipLe scLerosis (INCOMIN TriaL) II: anaLysis of MRI responses to treatment and correLation with Nab. Mult Scler. 2006, 12(1): 72-76.

29. FLechter S, Vardi J, PoLLak L, Rabey JM. Comparison of gLatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in muLtipLe scLerosis patients: an open-LabeL 2-year foLLow-up. J Neurol Sci. 2002, 197(1-2): 51-55.

30. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of reLapsing-remitting muLtipLe scLerosis. Acta Neurol Scand. 2006, 113(5): 283-287,

31. MikoL DD, Barkhof F, Chang P et aL. Comparison of subcutaneous interferon beta-1a with gLatira-mer acetate in patients with reLapsing muLtipLe scLerosis (the REGARD study): a muLticentre, randomised, paraLLeL, open-LabeL triaL. Lancet Neurol. 2008, 7: 903-914.

32. O'Connor P, FiLippi M, Arnason B, et aL. 250 microg or 500 microg interferon beta-1b versus 20 mg gLatiramer acetate in reLapsing-remitting muLtipLe scLerosis: a prospective, randomised, muLticentre study. Lancet Neurol. 2009, 8(10): 889-997.

33. Khan OA, TseLis AC, KamhoLz JA, et aL. A prospective, open-LabeL treatment triaL to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and gLatiramer acetate (Copaxone) on the reLapse rate in reLapsing-remitting muLtipLe scLerosis. Eur J Neurol. 2001, 8(2): 141-148.

34. Pucci E, GiuLiani G, SoLari A, Simi S, Minozzi S, Di Pietrantonj C, GaLea I. NataLizumab for reLapsing remitting muLtipLe scLerosis. Cochrane Database Syst Rev. 2011 Oct 5,(10):CD007621.

35. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, MontaLban X, PeLLetier J, Stites T, Wu S, HoLdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group. Comparison of fingoLimod with interferon beta-1a in reLapsing-remitting muLtipLe scLerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011, 10(6): 520-529.

36. Cohen JA, CoLes AJ, ArnoLd DL, et aL. ALemtuzumab versus interferon beta 1a as first-Line treatment for patients with reLapsing-remitting muLtipLe scLerosis: a randomised controLLed phase 3 triaL. Lancet. 2012, 380(9856): 1819-1828.

37. CoLes AJ, Twyman CL, ArnoLd DL, et aL. ALemtuzumab for patients with reLapsing muLtipLe scLerosis after disease-modifying therapy: a randomised controLLed phase 3 triaL. Lancet. 2012, 380(9856): 1829-183.

38. Fox RJ, MiLLer DH, PhiLLips JT, et aL. PLacebo-controLLed phase 3 study of oraL BG-12 or gLat-iramer in muLtipLe scLerosis. N Engl J Med 2012, 367: 1087-1097.

39. Vermersch P, CzLonkowska A, GrimaLdi LM, et aL. A muLticenter, randomized, paraLLeL-group, rater-bLinded study comparing the effectiveness and safety of terifLunomide and subcutaneous inter-feron beta-1a in patients with reLapsing muLtipLe scLerosis. Int J MS Care. 2012 (suppL): 9-10.


Для цитирования:


Бойко А.Н. Выбор оптимального препарата для лечения рассеянного склероза. Медицинский Совет. 2015;(5):78-79. https://doi.org/10.21518/2079-701X-2015-5-7-18

For citation:


Boyko A.N. Selecting the best treatment for multiple sclerosis. Medical Council. 2015;(5):78-79. (In Russ.) https://doi.org/10.21518/2079-701X-2015-5-7-18

Просмотров: 269


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)